Boston, Massachusetts 02446


Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo


Inclusion Criteria: - Greater than 18 years old - Hypotensive requiring vasopressors - Suspected Infection Exclusion Criteria: - Pregnant - Liver Failure (ALT or AST > 120) - Rhabomyolysis (CPK > 3x normal) - Comfort care measures status - Chronic Liver Disease (Cirrhosis) - Use of Cyclosporin, Digoxin, Statins - Patients who are unable to take medications by mouth or NGT



Primary Contact:

Principal Investigator
Michael W Donnino, MD
Beth Israel Deaconess Medical Center

Backup Contact:


Location Contact:

Boston, Massachusetts 02446
United States

Michael Donnino, MD
Phone: 617-667-7000

Site Status: Recruiting

Data Source:

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.